Publication date: Dec 04, 2024
Monoclonal antibodies (mAbs) targeting the SARS-CoV-2 Spike protein were deployed during the COVID-19 pandemic. While all of the clinically authorized mAbs were eventually defeated by SARS-CoV-2 variants, they were highly effective in preventing disease progression when given early in the course of the disease. The experience with mAbs to SARS-CoV-2 offers important lessons for the use of mAbs in future infectious disease emergencies, such as choosing mAbs that target conserved epitopes and designing cocktails to reduce the emergence of escape variants. Planning for future use must include the creation of infusion centers and the development of strategies to minimize the emergence of escape variants.
Concepts | Keywords |
---|---|
Antibodies | Antibodies |
Cocktails | Cov |
Future | Covid |
Lessons | Deployed |
Pandemic | Emergence |
Escape | |
Future | |
Lessons | |
Mabs | |
Monoclonal | |
Pandemic | |
Sars | |
Spike | |
Targeting | |
Variants |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | COVID-19 Pandemic |
disease | MESH | disease progression |
disease | MESH | infectious disease |
pathway | REACTOME | Infectious disease |
disease | MESH | emergencies |